11/15/2010

Actavis has notified Labopharm of its FDA filing for a generic version of Oleptro, the latter's once-daily treatment for depression. Labopharm, which is reviewing the formal notice, has market exclusivity for the drug through Feb. 2, 2013.

Full Story:
Reuters

Related Summaries